Extended Data Fig. 2: STK11 alterations and sotorasib efficacy.
From: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
(a) Kaplan-Meier curves of PFS according to STK11 mutation status in patients treated with sotorasib (left panel) or docetaxel (right panel) from CB200. (b) Kaplan-Meier curves of OS according to STK11 mutation status in patients treated with sotorasib (left panel) or docetaxel (right panel) from CB200. (c) Kaplan-Meier curves of PFS (left panel) and OS (right panel) according to STK11 mutation status in patients treated with sotorasib from CB100. (d) Kaplan-Meier curves of PFS (top panels) and OS (bottom panels) according to STK11 mutation status in KEAP1 WT patients treated only with sotorasib from CB200 (left) or CB100 (right). CB100, CodeBreaK 100; CB200, CodeBreaK 200; KRAS, Kirsten rat sarcoma virus; MUT, mutant; OS, overall survival; PFS, progression-free survival; WT, wild-type.
